News

Inovio will acquire the rights to agreements Valentis made with IDM Pharma, Innogenetics and Pharmexa. Innogenetics and Pharmexa are currently conducting separate phase I trials of DNA vaccines

Fibromyalgia is a musculoskeletal pain and fatigue disorder for which the cause is still unknown. The trial will investigate the efficacy, safety and tolerability of AD 337 in

Rifaximin could be a breakthrough treatment for irritable bowel syndrome (IBS) as researchers believe it is the first possible treatment for the potential causative factors of the disorder.

Arteriocyte’s trial is among the first to target heart disease with stem cell treatments The study is evaluating the safety of ACY001, an adult stem cell therapy harvested

The injunction prohibits Mylan Pharmaceuticals and Dr Reddy's Laboratories from selling their proposed generic risperidone products in the US until the patent on Risperdal expires in 2007. The

An AMPA/kainate (AK) receptor antagonist, tezampanel offers a non-narcotic, non-vascular approach to the management of headache pain and represents a potentially promising alternative to current migraine treatments. The

The interim results demonstrate that all Albuferon treatment groups consistently performed favorably compared to the pegylated interferon alpha treatment group, based on patient-reported disability days and health-related quality

The Ad5-TRAIL gene therapy for prostate cancer research trial is a phase I study designed to test the optimal dosage at which the therapeutic agent can safely be

The FDA sent a letter to Neurochem in August that requested additional efficacy information, as well as a safety update of Kiacta before it would issue approval. The